---
title: "BDSX.US (BDSX.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/BDSX.US/news.md"
symbol: "BDSX.US"
name: "BDSX.US"
parent: "https://longbridge.com/zh-CN/quote/BDSX.US.md"
datetime: "2026-03-13T16:47:11.818Z"
locales:
  - [en](https://longbridge.com/en/quote/BDSX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BDSX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BDSX.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/BDSX.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/BDSX.US/news.md)


# BDSX.US (BDSX.US) — 相关新闻

### [Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference](https://longbridge.com/zh-CN/news/278986808.md)
*2026-03-13T05:14:33.000Z*
> Biodesix (NASDAQ: BDSX) is focused on developing diagnostic tests for lung disease, with five lung tests currently on th

### [Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of "Moderate Buy" from Brokerages](https://longbridge.com/zh-CN/news/278207812.md)
*2026-03-07T09:01:02.000Z*
> Biodesix, Inc. (NASDAQ:BDSX) has received a consensus rating of "Moderate Buy" from six analysts, with one sell rating a

### [Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference](https://longbridge.com/zh-CN/news/278099385.md)
*2026-03-06T12:38:21.000Z*
> Biodesix (NASDAQ:BDSX) presented its growth strategy and financial goals at the TD Cowen Healthcare Conference, focusing

### [Monashee Investment Management LLC Cuts Holdings in Biodesix, Inc. $BDSX](https://longbridge.com/zh-CN/news/277354794.md)
*2026-03-01T12:27:21.000Z*
> Monashee Investment Management LLC has significantly reduced its holdings in Biodesix, Inc. (NASDAQ:BDSX) by 95% during 

### [Biodesix: Strengthened Balance Sheet, Expanding Sales Force, and Modest Revenue Outperformance Support Buy Rating at Attractive 1x Sales Valuation](https://longbridge.com/zh-CN/news/277247239.md)
*2026-02-27T20:55:22.000Z*
> Biodesix has received a Buy rating from analyst Daniel Brennan of TD Cowen, with a price target of $30. The rating is su

### [Lake Street Reaffirms Their Buy Rating on Biodesix (BDSX)](https://longbridge.com/zh-CN/news/277213279.md)
*2026-02-27T14:15:58.000Z*
> Lake Street has reaffirmed a Buy rating on Biodesix (BDSX) with a price target of $40.00, as reported by Thomas Flaten. 

### [Docebo Inc. reports strong Q4 results in 2025, highest gross bookings since 2021. Strong growth in Adjusted EBITDA margins.](https://longbridge.com/zh-CN/news/277189114.md)
*2026-02-27T11:07:40.000Z*
> In Toronto, Docebo Inc. (NASDAQ: DCBO; TSX: DCBO) revealed its financial outcomes for the quarter and fiscal year conclu

### [Biodesix (BDSX) was upgraded to a Buy Rating at William Blair](https://longbridge.com/zh-CN/news/277130908.md)
*2026-02-27T02:15:29.000Z*
> Biodesix (BDSX) has been upgraded to a Buy rating by William Blair analyst Andrew Brackmann, who has a 4-star rating and

### [Biodesix | 10-K: FY2025 Revenue Beats Estimate at USD 88.5 M](https://longbridge.com/zh-CN/news/277096169.md)
*2026-02-26T21:10:36.000Z*